Dr. Xiuping Yu
Associate Professor
Department of Biochemistry and Molecular Biology
Department of Urology
LSU Health Shreveport

## Education

Nankai University, Tianjin, China	B.S.	06/1991	Biochem & Mol Biology
Dalian Medical University, Dalian, China	M.S	06/1994	Biochem & Mol Biology
Dalian Medical University, Dalian, China	Ph.D.	06/2000	Biochem & Mol Biology
Medical College of Georgia, Augusta, GA	Postdoctoral	04/2003	Biochem & Mol Biology
Vanderbilt University, Nashville, TN	Postdoctoral	09/2008	Urologic Surgery



Dr. Yu is an Associate Professor with LSU Health Shreveport. Dr. Yu's research primarily focuses on the study of neuroendocrine prostate cancer. Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer-related deaths among American men. Androgen deprivation therapy is the gold standard treatment for advanced PCa. Patients initially respond well, resulting in tumor regression, but the tumors ultimately progress to castrate-resistant PCa. Moreover, once PCa becomes castrate-resistant, an aggressive neuroendocrine (NE) phenotype ensues with high morbidity and an average survival of less than 1.5 years. There is currently no effective treatment for PCa with a prominent NE phenotype. Identifying the mechanisms through which the NE phenotype arises is critical for the

development of novel therapeutics against PCa.